Tom Darell, CEO of Nord Pool, shares his expertise on the intricacies of the European power market. He discusses the complexities of futures and derivative contracts, the impact of renewable energy on market volatility, and the shift to tech-driven trading. Darell highlights the importance of data transparency and the evolving role of energy storage solutions, like vehicles, in enhancing system flexibility. He also examines the challenges and innovations in energy infrastructure and the need for a unified power pricing structure across Europe.

Dive into the power of storytelling and its motivational impact. Explore the unpredictable market dynamics shaped by media narratives and geopolitical tensions, including internet disruptions in Europe. Discover insights on investing in precious metals, particularly the contrasting nature of gold and silver. Reflect on the Russian military's recruitment struggles amid the Ukraine conflict. Finally, consider the implications of recent elections on financial markets and the complex intersection of politics, health, and AI.

Dette er en republisering av intervjuet Tid er penger gjorde med Kjetil Hatlebrekke i 2022. Kjetil døde dessverre i 2023 etter lang tids sykdom. Kjetil Hatlebrekke fra Volda jobbet innen norsk etterretningstjeneste og internasjonalt innen etterretningsfaget. Han var forfatter, underviser, foreleser, rådgiver, offiser, operatør og instruktør i seksjon for spesiell innhenting, E 14, med operativ erfaring fra Bosnia, Kosovo, Midtøsten/Irak og Afghanistan. Han tjenestegjorde i Forsvaret siden 1990. Han tok doktorgrad i etterretning og to mastergrader i krig- og konfliktstudier ved King’s College London hvor han også var gjesteforsker. Han mottok E-tjenestens fortjenstmedalje i 2019 som den første som ble hedret offentlig.Han ble 53 år gammel. Hosted on Acast. See acast.com/privacy for more information.

Jens Nordvig, a former analyst turned serial entrepreneur, delves into a wealth of finance insights. He navigates the challenges facing the Norwegian Krone and discusses innovative hedging strategies. The dialogue covers the impact of AI and alternative data on finance, examining how technology transforms investment approaches. Jens also shares his experiences through key economic events, emphasizing the importance of diverse perspectives in understanding market dynamics. This conversation serves as a masterclass in macroeconomics and data-driven strategies.

Explore the intricate ties between global politics and economics, revealing how elections sway market dynamics. Delve into the influence of U.S. electoral outcomes on European markets and tech stocks. Discover the volatility of cryptocurrencies, including Bitcoin, and how recent events shape their trajectories. The conversation highlights the ethical challenges in journalism amidst geopolitical narratives, while exploring the complexities of prediction markets and the role of social media in shaping economic perceptions.

General Ben Hodges, former commander of US Army Europe, shares his extensive military experience and insights into current geopolitical tensions. He discusses the complexities of military leadership and NATO coordination in Europe, emphasizing lessons learned since the Cold War. The conversation delves into historical interventions, contrasting the U.S. invasion of Iraq with the ongoing conflict in Ukraine, and scrutinizes the Russian military landscape, highlighting internal dissent and the disconnect in leadership.

Jens Norvig, an economist at Goldman Sachs, shares intriguing insights into market dynamics and geopolitical influences. He analyzes the volatility of the QQQ ETF and the effects of European regulations on passive fund management. The impact of interest rate cuts in the U.S. bond market is discussed, alongside rising inflation challenges. Norvig also explores how fintech innovations are reshaping the industry and emphasizes the need for better consumer banking options through new services. With a keen eye on financial trends, he navigates the future of investment strategies.

Tid er penger har hatt gleden av å ha advokat og skatte-ekspert Harald Hauge i Wikborg Rein som gjest i podcasten, for å kunne forklare oss nøyaktig hvordan skattesystemet nå fungerer, hvorfor alle flytter og er så sure og hva det betyr i praksis. Utrolig nok er virkeligheten mye verre enn vi trodde. Og vi trodde det verste. Her er noen vekttall i skatt som alle kunne trenge. Hosted on Acast. See acast.com/privacy for more information.

Dette er episode 287 av Tid er penger. I denne episoden handler det om krona, om hva du gjør når du har virkelig vunnet økonomisk, om markedet og bittelitt om valget. Veldig mange lyttere av Tid er penger diskuterer daglig det som skjer i markedene, verden osv på Tid er pengers Discord-kanal. Du kan melde deg på ved å klikke her: https://discord.gg/AC7gPsw7VMPå Patreon kan du høre hele episoden, uten promo, reklame: https://www.patreon.com/tiderpengerVil du melde deg på nyhetsbrevet til Tid er penger, gjør du det her: https://tiderpenger.substack.com/ Hosted on Acast. See acast.com/privacy for more information.

Tid er penger har gleden av å ha Dr. Steve som gjest i dagens podcast, der vi får stille mange dumme spørsmål rundt diverse kreftbehandlinger som er under utvikling i dag, som han kan svare på i dybden. Selve episoden er ganske teknisk og han bruker mange kompliserte termer. Vi har laget en oppsummering av det han snakker om under, og gjorde det på engelsk for at det skulle være helt korrekt ref hans ord og uttrykk:1. *HPV Vaccine*: A preventative vaccine for cervical cancer caused by the human papillomavirus (HPV). It's also effective against other cancers caused by HPV, such as head and neck, rectal, and penile cancers.  2. *Hepatitis B Vaccine*: Mentioned as an anti-cancer vaccine since chronic hepatitis B can lead to liver cancer.  3. *mRNA Technology*: Used in vaccines and treatments, mRNA technology instructs cells to produce proteins that stimulate the immune system to target cancer cells. It's being researched for various cancers, including pancreatic cancer and melanoma.  4. *Immune Therapy (PDL-1 Inhibitors)*: Antibodies created in the laboratory to help the immune system recognize and attack cancer cells, used in a variety of cancers.  5. *CAR-T Cell Therapy (Chimeric Antigen Receptor T-Cell Therapy)*: A treatment where a patient's T cells are engineered to better recognize and attack cancer cells, currently approved for certain blood cancers like lymphomas and leukemias.  6. *Viral Oncolytic Therapy*: Uses viruses, such as the measles virus, to infect and kill cancer cells, particularly being researched for multiple myeloma.  7. *Proton Beam Therapy*: An advanced form of radiation therapy that uses a beam of protons to precisely target and kill cancer cells while sparing surrounding healthy tissue.  8. *Monoclonal Antibodies*: Proteins manufactured in the lab that can target specific antigens on cancer cells, used in various cancers for both treatment and diagnostic purposes.  9. *Tyrosine Kinase Inhibitors*: Targeted therapies that block specific enzymes (tyrosine kinases) involved in the growth and spread of cancer cells.  10. *Research on Universal T-Cell Receptor Targeting Cancer Cells*: Early-stage research into T-cell receptors that can recognize and kill a broad range of cancer types via a specific protein, potentially leading to a more universal cancer treatment.   Hosted on Acast. See acast.com/privacy for more information.